144 related articles for article (PubMed ID: 16202591)
41. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
Schweinitz A; Steinmetzer T; Banke IJ; Arlt MJ; Stürzebecher A; Schuster O; Geissler A; Giersiefen H; Zeslawska E; Jacob U; Krüger A; Stürzebecher J
J Biol Chem; 2004 Aug; 279(32):33613-22. PubMed ID: 15150279
[TBL] [Abstract][Full Text] [Related]
42. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
43. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
44. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
45. Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase.
Ruppert C; Mahavadi P; Wygrecka M; Weaver TE; Magdolen V; Idell S; Preissner KT; Seeger W; Günther A; Markart P
Thromb Haemost; 2008 Dec; 100(6):1185-92. PubMed ID: 19132247
[TBL] [Abstract][Full Text] [Related]
46. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
[TBL] [Abstract][Full Text] [Related]
47. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
48. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties.
Joossens J; Ali OM; El-Sayed I; Surpateanu G; Van der Veken P; Lambeir AM; Setyono-Han B; Foekens JA; Schneider A; Schmalix W; Haemers A; Augustyns K
J Med Chem; 2007 Dec; 50(26):6638-46. PubMed ID: 18052026
[TBL] [Abstract][Full Text] [Related]
49. Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
Lamy S; Lafleur R; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
J Cell Biochem; 2007 Jan; 100(1):100-11. PubMed ID: 16823770
[TBL] [Abstract][Full Text] [Related]
50. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
52. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
53. Effects of urokinase-type plasminogen activator in the acquisition, expression and reinstatement of cocaine-induced conditioned-place preference.
Bahi A; Kusnecov AW; Dreyer JL
Behav Brain Res; 2008 Aug; 191(1):17-25. PubMed ID: 18436315
[TBL] [Abstract][Full Text] [Related]
54. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
55. Progress of tissue injury in appendicitis involves the serine proteases uPA and PAI-1.
Solberg A; Holmdahl L; Falk P; Willén R; Palmgren I; Ivarsson ML
Scand J Gastroenterol; 2009; 44(5):579-84. PubMed ID: 19153874
[TBL] [Abstract][Full Text] [Related]
56. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
57. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
58. Evolving role of uPA/uPAR system in human cancers.
Dass K; Ahmad A; Azmi AS; Sarkar SH; Sarkar FH
Cancer Treat Rev; 2008 Apr; 34(2):122-36. PubMed ID: 18162327
[TBL] [Abstract][Full Text] [Related]
59. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
60. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Lamy PJ; Verjat T; Servanton AC; Paye M; Leissner P; Mougin B
Am J Clin Pathol; 2007 Sep; 128(3):404-13. PubMed ID: 17709314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]